Comorbidity prevalence and incidence in cancer survivors: a longitudinal All of Us study
Lee, Jung Ae ; Pakpahan, Ratna ; Amante, Daniel J ; Gerber, Ben S ; Yang, Lin
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Subject Area
Files
Embargo Expiration Date
Link to Full Text
Abstract
Comorbidities worsen cancer survival but patterns of pre-existing and new onset comorbidities among cancer survivors are unknown. We investigated self-reported and clinically diagnosed comorbidity among cancer survivors in the All-of-Us program's national database. Eight highly prevalent comorbidities were identified using self-reported data from the personal health history (PHH) survey among cancer survivors (n = 20,534) and non-cancer adults (n = 113,628), and validated among cancer survivors (n = 26,978) using data from electronic health records (EHRs). Among 5-year survivors (n = 9,174) documented in EHR, we further estimated the incidence of new-onset comorbidities. The most prevalent comorbidities identified in PHH data were hypertension (40.5%), osteoarthritis (28.4%), depression (28.0%), and obesity (23.2%). EHR data identified pre-existing comorbidities: hypertension (43.3%), osteoarthritis (29.4%), depression (19.4%), and obesity (19.1%). During five-year survival, over 50% cancer survivors developed at least one new comorbidity, and over 25% developed two or more. The onset of new comorbidities showed a sharp increase in the first-year post-diagnosis. Incidence rates varied by age, race and ethnicity. Future research is needed to develop effective strategies to prevent newly onset comorbidities during and after cancer treatment.
Source
Lee JA, Pakpahan R, Amante DJ, Gerber BS, Yang L. Comorbidity prevalence and incidence in cancer survivors: a longitudinal All of Us study. JNCI Cancer Spectr. 2025 Oct 8:pkaf093. doi: 10.1093/jncics/pkaf093. Epub ahead of print. PMID: 41059983.